At-home skin care devices is a booming market, says Kline report
PARSIPPANY, N.J. — At-home skin care devices are expected to be the next billion-dollar market, according to a recently published report by consulting and research firm Kline & Co.
In the "At-home Skin Care Devices 2011: U.S. Market Analysis and Opportunities" report, Kline pegs the market at close to $1 billion at the retail level for 2011, with exceptional growth expected for the next five years. Kline’s report is the first of its kind to take an in-depth look at the market for this emerging class of power-operated devices designed for acne elimination, anti-aging treatment and daily cleansing.
“We knew this market was really taking off, but even we were shocked by its sheer size,” stated Karen Doskow, industry manager for Consumer Products at Kline. “Clearly, these devices are finding a very receptive and growing audience of savvy consumers looking to save time and money by avoiding regular trips to the doctor for those in-office procedures that were once commonplace in more robust economic times.”
With more consumers staying at home, either due to job losses or by virtue of the work-at-home/telecommuting trend, Doskow said the direct sales channel — which includes home shopping networks, infomercials and e-commerce — is the primary means of distribution, with about 60% of the total market share.
While sonic cleansing products, led by Clarisonic, top the list as the highest growth segment, acne treatment devices are the fastest-growing. Meanwhile, anti-aging devices are expected to grow by 50% this year alone, benefiting from consumers’ demand for products to reduce the appearance of fine lines, wrinkles and age spots. Kline’s recent Professional Skin Care research revealed that anti-aging is the No. 1 skin care concern for consumers, with topical product sales in this category comprising more than 40% of the market.
“This dynamic provides a perfect opportunity for device and topical product manufacturers to pair their products together to meet consumers’ anti-aging needs,” Doskow added.
"At-home Skin Care Devices 2011: U.S. Market Analysis and Opportunities" also points to strong opportunities for manufacturers to develop mass-market product options for price-sensitive consumers and to diversify their product lines to appeal to a wide range of age groups, from teens to mature consumers.
American Diabetes Association, Lilly team for annual Victory Over Diabetes event
ATLANTA — The American Diabetes Association, with help from drug maker Eli Lilly, once again is hosting a free communitywide event in Atlanta that’s designed to educate African-Americans on diabetes management.
The annual Victory Over Diabetes event, which will be held on Aug. 20 at the Georgia International Convention Center, will offer educational workshops, health screenings and resources on diabetes. On hand at the event will be actor Anthony Anderson, who is the new spokesman for Lilly’s Fearless African-Americans Connected and Empowered program. Diabetes is said to affect 1-in-7 adults in Georgia, according to the Georgia Department of Community Health.
"Being diagnosed with Type 2 diabetes is life changing, but with the help of a team of medical professionals, I’ve taken control of my disease," Anderson said. "I’m eager to share my story at Victory Over Diabetes and hope to encourage the African-American community in Georgia to feel empowered to take control of their own health."
Click here for more information.
Savient gout drug shows improvements, according to study
EAST BRUNSWICK, N.J. — Patients with gout taking a drug made by Savient Pharmaceuticals experienced "significant" improvements, according to results of two late-stage clinical trials published in the Journal of the American Medical Association.
Savient said results of phase-3, placebo-controlled trials of Krystexxa (pegloticase) showed that the drug produced significant and sustained reductions in uric acid levels in 42% patients with refractory chronic gout and clinical improvements in a substantial proportion of patients for six months. In addition, 40% of patients received complete resolution of one or more tophi, crystalline urate deposits in the joints, skin and cartilage, compared with 7% of those taking placebo.
The trials were conducted on 212 patients in the United States, Canada and Mexico between June 2006 and October 2007 who had severe gout, allopurinol intolerance or refractoriness, and serum uric acid concentration of 8 mg per deciliter or more. Patients received 12 two-week intravenous infusions with either 8 mg of Krystexxa every two weeks, Krystexxa alternating with placebo or placebo alone.